Stempro 34 nutrient

RBL-MRGPRX2 cells were generated as previously described [24 (link)]. RBL-MRGPRX2 cells and their parental RBL-2H3 (herein referred to as RBL) counterparts were maintained at 37 °C, in a humidified incubator with 5% CO₂, in adherent cell cultures in low-glucose DMEM (cat # 01-050-1A, Biological Industries, Beit-Haemek, Israel) supplemented with 10% FBS (cat # 12657, GIBCO, Grand Island, NY, USA), 2 mM L-Glutamine (cat # 03-020-1A, Biological Industries), 100 μg/mL streptomycin and 100 U/mL penicillin and 12.5 U/mL nystatin (Biological Industries, Beit-Haemek, Israel), except for RBL-MRGPRX2 cells that were additionally supplemented with 1 mg/mL of G418 (cat # A1720, Sigma Aldrich, St Louis, MO, USA). LAD-2 cells (a kind gift from Dr. A.S. Kirshenbaum and Dr. D. Metcalfe, Laboratory of Allergic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA) were cultured in StemPro-34 (cat # 10640-019, GIBCO) supplemented with 1× StemPro-34 Nutrient, 2 mM L-Glutamine (cat # 03-020-1A, Biological Industries), 100 U/mL penicillin and 100 μg/mL streptomycin (cat # 03-032-1B, Biological Industries), and 100 ng/mL hSCF (cat # 300-07, Peprotech, Rocky Hill, NJ, USA).

RBL cells stably expressing N-terminally tagged hemagglutinin (HA) human MRGPRX2 (RBL-MRGPRX2) were previously described [12 (link)]. Cells were maintained as adherent cell cultures in low glucose DMEM (cat no. 01-050-1A, Biological Industries, Beit-Haemek, Israel) supplemented with 10% FBS (cat no. 12657, GIBCO, Grand Island, NY, USA), 2 mM L-Glutamine (cat no. 03-020-1A, Biological Industries), 100 μg/mL streptomycin, and 100 U/mL penicillin, 12.5 U/mL nystatin (cat no. 03-032-1B, Biological Industries), and 1 mg/mL of G418 (cat no. A1720, Sigma Aldrich, St. Louis, MO, USA), at 37 °C in a humidified incubator with 5% CO₂. LAD-2 cells (a kind gift from Dr. A.S. Kirshenbaum and Dr. D. Metcalfe, Laboratory of Allergic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA) were cultured in StemPro-34 (cat no. 10640-019, GIBCO) supplemented with 1× StemPro-34 Nutrient, 2 mM L-Glutamine (cat no. 03-020-1A, Biological Industries), 100 U/mL penicillin and 100 μg/mL streptomycin (cat no. 03-032-1B, Biological Industries), and 100 ng/mL hSCF (cat no. 300-07, Peprotech, Rocky Hill, NJ, USA).

RBL cells stably expressing N-terminally tagged hemagglutinin (HA) human MRGPRX2 (RBL-MRGPRX2) were generated as previously described (20 (link)). Cells were maintained at 37°C in a humidified incubator with 5% CO₂ in adherent cell cultures in low glucose DMEM (cat no. 01-050-1A, Biological Industries, Beit-Haemek, Israel) supplemented with 10% FBS (cat no. 12657, GIBCO, Grand Island, NY), 2 mM L-Glutamine (cat no. 03-020-1A, Biological Industries), 100 μg/mL streptomycin and 100 U/mL penicillin, 12.5 U/mL nystatin (Biological Industries) and 1 mg/mL of G418 (cat no. A1720, Sigma Aldrich). LAD-2 cells (a kind gift from Dr. A.S. Kirshenbaum and Dr. D. Metcalfe, Laboratory of Allergic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD) were cultured in StemPro-34 (cat no. 10640-019, GIBCO) supplemented with 1x StemPro-34 Nutrient, 2 mM L-Glutamine (cat no. 03-020-1A, Biological Industries), 100 U/mL penicillin and 100 μg/mL streptomycin (cat no. 03-032-1B, Biological Industries), and 100 ng/mL hSCF (cat no. 300-07, Peprotech, Rocky Hill, NJ).